Main results
No meta-analysis could be performed.
Authors' conclusions
As no studies that met the criteria were found, this review is unable to support or refute the benefits of singing as a therapy for people with cystic fibrosis. Future randomised controlled trials are required to evaluate singing therapy for people with cystic fibrosis.
P L A I N L A N G U A G E S U M M A R Y
The effects of singing on lung function and quality of life for children and adults with cystic fibrosis Individuals with cystic fibrosis are at risk for respiratory infections due to too much mucus in their airways. Airway clearance is therefore an important part of cystic fibrosis management. Increasing anecdotal evidence suggests that singing may support lung function and enhance quality of life of people with cystic fibrosis. We searched for trials using the standard search module of the Cochrane Cystic Fibrosis and Genetic Disorders Group, as well as extensive searches in the relevant databases and publications. We did not find any randomised controlled trials that evaluated the benefits of singing in people with cystic fibrosis. The effects of singing in addition to standard therapy for people with cystic fibrosis remain unknown.
B A C K G R O U N D

Description of the condition
Cystic fibrosis (CF) is a genetically inherited life-threatening condition that affects major organs, such as the lungs, pancreas, liver and kidneys. Individuals with CF produce abnormally excessive thick mucus in the airways, which makes them more susceptible to lung diseases. Repeated infections in the airways lead to irreversible lung damage (Phelan 1994) . The management of CF involves a multifaceted daily treatment regimen that usually includes airway clearance physiotherapy, physical exercise, taking pancreatic enzymes and other medications, as well as hospital admissions. Such an intensive treatment regime may have a negative psychosocial impact on children and adolescents (Glasscoe 2008), but particularly on adolescents (D'Auria 2000). Previous studies identified that individuals with CF are likely to have poor quality of life (QoL) (Quittner 2008).
Description of the intervention
Several studies have reported that people such as trained singers, who learn diaphragmatic breathing, exhibit more efficient pulmonary capacity than non-trained singers (Collyer 2009; Formby 1987) . In people with respiratory disease, anecdotal evidence suggests that adjunctive therapies that include breathing manoeuvres, such as singing, have significant health benefits for the disease process (Stacy 2002), as well as for psychological well being (Unwin 2002). Singing is not merely a form of vocal expression, but also a complex physical activity. Singing requires well-controlled respiratory behaviour due to the greater range of pitch accessed during singing compared with speaking, greater length of musical phrases than spoken language, and the greater dynamic range used in singing songs. To meet these artistic as well as physical challenges, singers employ the diaphragmatic breathing method. The diaphragm as a primary inspiratory muscle generates the necessary subglottal pressure for singing. Louder and higher sounds are associated with higher lung volumes (Sundberg 1987) . Respiratory muscles such as the transversus abdominis, external and internal obliques, and the intercostals must also be fully engaged to regulate air flows during singing. Thus, classically trained singers exhibit efficient breath-management and greater use of their lung capacity than non-singers (Collyer 2009; Leanderson 1988; Thomasson 1999). Respiratory muscles also play an important role in producing effective cough, which is essential for lung health in people with CF. For an effective cough, high subglottal pressure and strong expiratory force are necessary (Kang 2006). For increasing one's ability to produce maximal expiratory pressure, it is necessary to employ diaphragmatic breathing because it helps to increase lung volumes and strengthen respiratory muscle capacity (Spapienza 2002; Wiens 1999 
How the intervention might work
Singing as an intervention for respiratory conditions involves, in addition to the vocal cords and laryngeal apparatus, the activation of the muscles of the entire respiratory system through diaphragmatic breathing (Sundberg 1987). Diaphragmatic breathing can increase respiratory muscle strength, which leads to increased lung volume and effective cough (Kang 2006; Wiens 1999). Most songs contain musical phrases of greater length than spoken utterances, notes of various pitch, and changing dynamics (soft or loud), which actively engage and work the respiratory muscles. A singing intervention can be carried out in a one-to-one or group setting in a non-judgmental and supportive environment. The program needs to be of sufficient length and intensity to allow participants to master the diaphragmatic breathing technique. This can vary from individual to individual, depending on their age, background, illness severity, past experience with singing and music generally and the relationship between the singing facilitator and the patient. A study of people with emphysema (over 60 years of age) indicated that at least two half-hour sessions are necessary for learning the diaphragmatic breathing method correctly (Engen 2005).
Why it is important to do this review
A recent Cochrane systematic review identified very few research studies on non-medical interventions in the field of CF (Glasscoe 2008). Despite progress in medical treatment for CF, psychological therapies to improve emotional well-being have not been forthcoming (Elgudin 2004). To date, CF treatment has been dominated by rigorous medical treatments, which are, of course, essential. However, the strong emphasis on medical treatment for CF may reflect a disease-oriented view, in which only the physical symptoms are treated. A single medical treatment cannot provide the care and management required to improve all dimensions of QoL in people living with CF. A multidisciplinary treatment regimen can be effective in meeting the complex needs of individuals with CF. Research in health psychology supports this view and provides strong evidence that numerous factors influence both illness and well-being (Bernard 1994; Knight 1998). These should be taken into account when providing a health service whose aim is to optimise health outcomes, both medical and psycho-social. Singing is a relatively inexpensive adjunct intervention that can potentially enhance QoL and de-medicalise at least some of the treatment regimens for people with CF. Thus, we have conducted a review on the efficacy of singing as an adjunctive intervention for people with CF to help guide clinical practice.
O B J E C T I V E S
To assess the effects of singing as an adjunctive therapy for children and adults with CF on outcomes including QoL, morbidity, respiratory muscles and pulmonary function.
M E T H O D S Criteria for considering studies for this review
Types of studies
Randomised or quasi-randomised clinical trials.
Types of participants
People with CF, of any age, diagnosed on the basis of sweat testing or genotype analysis.
Types of interventions
All types of singing intervention that included diaphragmatic breathing, which were carried out in a group or one-to-one setting, facilitated by singing instructors or teachers, voice coaches or trainers, or music therapists, for a minimum of two half-hour sessions. Studies comparing singing with a sham group that did not involve the activation of the respiratory muscles were to be considered. Studies using non face-to-face delivery format, such as DVD or CD were not considered as these formats could not address some important issues such as how to use the voice in a healthy way while singing, and to obtain immediate feedback on singing practice, posture and breathing technique. Further, individual or group singing sessions can also be adjusted to the levels of singers, which is hard to achieve through media, such as DVD or CD. 6. Adherence to other CF treatments (e.g. measured by a diary, self-evaluation check-list) 7. Psychological assessments measuring self-efficacy, depression and anxiety
Search methods for identification of studies
There were no language or publication restrictions.
Electronic searches
We searched the Group's Cystic Fibrosis Trials Register for relevant trials using the terms: 'cystic fibrosis' AND 'singing'. The Cystic Fibrosis Trials Register is compiled from electronic searches of the Cochrane Central Register of Controlled Trials 
Data collection and analysis
We did not find any eligible studies and were unable to carry out plans for analysis stated in the protocol. However, for future updates, if studies are included, we will follow the methods set out in the protocol.
Selection of studies
Two authors (JYI, AC) independently assessed studies for inclusion in the review based on the inclusion criteria stated above. If there was any disagreement in this process, they would have consulted with the third author (DK) and resolved by discussion.
Data extraction and management
Two authors (JYI, DK) would have independently extracted data from the eligible studies on to a standard data extraction form, and one author (JYI) would have entered the data into RevMan for analysis (RevMan 2008). DK would have checked the entered data. Trials that satisfied the inclusion criteria would have been reviewed and the following information would have been recorded: study setting, year of study, source of funding, participants recruitment details (including number of eligible people), inclusion and exclusion criteria, other symptoms, randomisation and allocation concealment method, numbers of participants randomised, blinding (masking) of participants, care providers and outcome assessors, duration of intervention, previous singing training, co-interventions, numbers of participants not followed up, reasons for withdrawals from study protocol (clinical, side-effects, refusal and other), details on side-effects of therapy, and whether intentionto-treat analyses were possible. We would have extracted data on the outcomes described previously at two points: short term (at less than one month) and longer term (over one month and up to six months, over six months and up to one year and annually thereafter). We would have requested further information from the authors where required.
Assessment of risk of bias in included studies
In order to assess the risk of bias, two review authors would have independently assessed the quality of the studies included in the review using the RevMan 'Risk of Bias' table as described in Chapter 8 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2008).
Generation of the allocation sequence
We would have graded each study for the generation of allocation sequence as follows:
1. Low risk of bias, if methods of randomisation include using a random number table, computer-generated lists or similar methods;
2. Uncertain risk of bias, if the trial was described as randomised, but no description of the methods used to allocate participants to treatment group was described; 3. High risk of bias, if methods of randomisation include alternation, the use of case record numbers, dates of birth or day of the week, and any procedure that was entirely transparent before allocation.
Allocation concealment
We would have assessed whether allocation was adequately concealed, to prevent both participants and investigators from foreseeing assignment.
1. Adequate (low risk of bias), if the allocation of participants involved a central independent unit, on-site locked computer, identically appearing numbered drug bottles or containers prepared by an independent pharmacist or investigator, or sealed opaque envelopes; 2. Unclear (unclear risk of bias), if the method used to conceal the allocation was not described; 3. Inadequate (high risk of bias), if the allocation sequence was known to the investigators who assigned participants, for example it was based on day of admission or case record number.
Blinding (or masking)
Due to the nature of the intervention, it is impossible to blind participants. We would have assessed each study as to whether the outcome assessors were blinded to treatment allocation (low risk of bias); unclear whether they were blinded (unclear risk of bias); or not blinded to treatment (high risk of bias).
Follow up
We would have graded each study as to whether numbers of and reasons for dropouts and withdrawals in all intervention groups were described; or whether it was specified that there were no dropouts or withdrawals.
1. Low risk of bias, if reasons for dropouts and withdrawals described;
2. Uncertain risk of bias, if insufficient or selective reporting of dropouts and withdrawals;
3. High risk of bias, if not reporting reasons for dropouts and withdrawals likely to be related to true outcome.
Selective outcome reporting
We would have tried to identify and report on any selective reporting in the included trials, ideally by comparing the trial protocol with the final published paper, but alternatively by comparing the 'Methods' and 'Results' sections of the published trial.
1. Low risk of bias, if all outcomes reported as being measured were reported; 2. Uncertain risk of bias, if it was unclear whether all measured outcomes were reported; 3. High risk of bias, if not all outcomes that were measured were reported.
Other potential sources of bias
We would have tried to identify any other sources of bias not reported elsewhere in the review and assessed their potential for putting the trial results at risk of bias.
Measures of treatment effect
An initial qualitative comparison of all the individually analysed studies would have examined whether pooling of results (metaanalysis) was reasonable. This would have taken into account differences in study populations, inclusion and exclusion criteria, interventions and outcome assessment. The results from studies that met the inclusion criteria and report any of the outcomes of interest would have been included in the subsequent meta-analyses. For the dichotomous outcome variables of each individual study, we would have calculated the odds ratio (OR) and 95% confidence intervals (CIs) using a modified intention-to-treat analysis (modified if there are missing values due to drop outs). We would have used the Cochrane statistical package RevMan 5.0 (RevMan 2008). Numbers needed to treat (NNT) would have been calculated from the pooled OR and its 95% CI applied to a specified baseline risk (from the control group) using an online calculator (Cates 2003). For continuous outcomes we would have calculated the mean difference (MD) and 95% CIs using RevMan 5 (RevMan 2008). If studies report outcomes using different measurement scales, the standardised mean difference would have been estimated.
Unit of analysis issues
Cross-over trials are not appropriate for this intervention and thus only the first arm of any cross-over trials would be included.
Dealing with missing data
The authors would have requested further information from the primary investigators where required.
Assessment of heterogeneity
We would have described any heterogeneity between the study results and tested this to see if it reached statistical significance using the chi-squared test. We would have considered heterogeneity to be significant when the P value was less than 0.10 (Higgins 2008). We also planned to use the I² statistic, to quantify inconsistency of the results of the studies as described in Chapter 9 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2008). We would have categorised heterogeneity such that a value of under 25% was considered low, around 50% was considered moderate and over 75% was considered a high degree of heterogeneity (Higgins 2003).
Assessment of reporting biases
If combination of data and meta-analysis (with at least 10 studies) was possible, we would have assessed publication bias using a funnel plot.
Data synthesis
We would have calculated the summary OR and mean differences with their 95% CIs using a fixed-effect model. We would have used a random-effects model whenever there were concerns about statistical heterogeneity, i.e. when there was at least moderate heterogeneity as defined above using the I² statistic, where I² is at least 50%. We will only combine 'other subjective scores' (see Secondary outcome 2) if we deem it clinically appropriate.
Subgroup analysis and investigation of heterogeneity
If there were sufficient studies included in the review and it was appropriate, we planned the following a priori sub-group analyses:
1. Children (under 18 years old) versus adults; 2. Severity of exacerbation (based on FEV 1 where over 80% is classified as mild; 50 to 79% is classified as moderate; 30 to 49% is classified as severe; and less than 30% is classified as very severe); 3. Type of singing intervention (e.g. type of training, i.e. individual or group singing, length of follow up); 4. Intervention conducted during an acute exacerbation versus non-exacerbation state.
Sensitivity analysis
Sensitivity analyses were also planned to assess the impact of the potentially important factors on the overall outcomes, if there were sufficient studies (10):
1. Variation in the inclusion criteria; 2. Risk of bias in the included studies, (particularly whether allocation was well concealed); 3. Differences in outcome measures; 4. Analysis using random-effects model; 5. Analysis by "treatment received" or "intention-to-treat".
R E S U L T S Description of studies
See: Characteristics of excluded studies; Characteristics of ongoing studies.
Results of the search
The electronic search yielded 194 studies. Initial screening of the abstracts of these studies was undertaken by JYI and AC. A total of 17 papers were reviewed for detailed assessment; of these, none fulfilled the inclusion criteria and two were excluded. For details, please see 'Characteristics of excluded studies' below. We have identified one ongoing study (Irons 2009).
Included studies
No study met the inclusion criteria.
Excluded studies
A music therapy study used pre-recorded music as an adjunct to regular chest physiotherapy for toddlers with CF (under 24 months old) and their caregivers (Grasso 2000). However, singing was not explored in this study. Another study investigated the effects of listening to Bach's Magnificat (a choir singing a religious work) on 40 adults with pneumonia or acute bronchitis (Roux 2007). Singing (as opposed to listening to music) was not part of the intervention in this study (Roux 2007).
Risk of bias in included studies
No studies were included in the review.
Effects of interventions
In the absence of any data, the effect of singing as a therapy for people with CF remains unknown.
D I S C U S S I O N
Summary of main results
No studies could be included in this review. Two excluded studies suggest that music may be beneficial as an adjunctive management strategy for people with CF; however, these studies looked at the effects of listening to music rather than actively singing. Future research on the efficacy of a non-expensive yet potentially effective therapy on respiratory muscles and psychosocial well-being is warranted.
A U T H O R S ' C O N C L U S I O N S Implications for practice
There is currently insufficient evidence to advocate singing as an adjunctive therapy in the management of people with CF.
Implications for research
Previous studies have demonstrated that singing has the therapeutic potential to enhance the quality of life of people with chronic respiratory disease, such as emphysema, asthma, and COPD (Engen 2005; Griggs-Drane 1999; Irons 2010; Wade 2002). Singing, at least certain types of singing that use diaphragmatic breathing, can strengthen respiratory muscles. The design of future RCTs should include detailed information about the singing intervention (vocal exercises, song type, pitch and dynamic range) and delivery format (individual or group), length and frequency of sessions and prescribed singing practice time. Trials evaluating short-term (acute admission), medium-term (up to and including 12 months) and longer-term outcomes (over 12 months) are also needed. Additionally, culturally appropriate musical items should be included, taking care that different songs make similar demands on the respiratory and vocal systems. Dose response effects should be assessed.
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